Comments on Immunogenicity Associated with Botulinum Toxin Treatment. <i>Toxins</i> 2019, <i>11</i>, 491

In contrast to the prevailing arguments presented in the current review, the incidence of neutralising antibody (NAb) formation is not a significant issue for any of the present type A therapeutic botulinum neurotoxin (BoNT) products. Furthermore, clinical non-responsiveness is poorly correlated wit...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Keith Foster, Matthew Beard
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	MDPI AG 2020-01-01
Reeks:	Toxins
Onderwerpen:	abobotulinumtoxin a botulinum neurotoxin (bont) immunogenicity incobotulinumtoxin a neutralising antibody (nab) onabotulinumtoxin a secondary non-responsiveness (snr)
Online toegang:	https://www.mdpi.com/2072-6651/12/2/71
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!